Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Sanofi India Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹2,612.88Overvalued by 23.78%vs CMP ₹3,428.00

P/E (22.8) × ROE (43.0%) × BV (₹326.00) × DY (2.19%)

₹1,737.22Overvalued by 49.32%vs CMP ₹3,428.00
MoS: -97.3% (Negative)Confidence: 68/100 (Moderate)Models: All 9: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹2,150.0822%Over (-37.3%)
Graham NumberEarnings₹1,065.9916%Over (-68.9%)
Earnings PowerEarnings₹2,069.8713%Over (-39.6%)
DCFCash Flow₹1,515.4613%Over (-55.8%)
Net Asset ValueAssets₹339.597%Over (-90.1%)
EV/EBITDAEnterprise₹2,742.319%Over (-20%)
Earnings YieldEarnings₹1,549.207%Over (-54.8%)
ROCE CapitalReturns₹2,266.019%Over (-33.9%)
Revenue MultipleRevenue₹1,311.235%Over (-61.7%)
Consensus (9 models)₹1,737.22100%Overvalued
Key Drivers: EPS CAGR -17.7% drags value — could be higher if earnings stabilize. | Wide model spread (₹340–₹2,742) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -17.7%

*Investments are subject to market risks

Analyst Summary

Sanofi India Ltd operates in the Pharmaceuticals segment, NSE: SANOFI | BSE: 500674, current market price is ₹3,428.00, market cap is 7,894 Cr.. At a glance, stock P/E is 22.8, ROE is 43.0 %, ROCE is 57.5 %, book value is 326, dividend yield is 2.19 %. The latest intrinsic value estimate is ₹1,737.22, around 49.3% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹2,013 Cr versus the prior period change of -29.4%, while latest net profit is about ₹414 Cr with a prior-period change of -31.3%. The 52-week range shown on this page is 6,410/3,151, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisSanofi India Ltd. is a Public Limited Listed company incorporated on 02/05/1956 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L242…

This summary is generated from the stock page data available for Sanofi India Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

64
Sanofi India Ltd scores 64/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health92/100 · Strong
ROCE 57.5% ExcellentROE 43.0% ExcellentD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money40/100 · Moderate
FII holding stable No changeDII holding down 1.72% MF sellingPromoter holding at 60.4% Stable
Earnings Quality60/100 · Moderate
OPM stable around 26% SteadyWorking capital: 20 days (improving) Efficient
Quarterly Momentum25/100 · Weak
Revenue (4Q): -9% YoY DecliningProfit (4Q): -21% YoY Declining
Industry Rank80/100 · Strong
P/E 22.8 vs industry 59.5 Cheaper than peersROCE 57.5% vs industry 16.4% Above peersROE 43.0% vs industry 15.2% Above peers3Y sales CAGR: -12% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 25, 2026, 11:44 pm

Market Cap 7,894 Cr.
Current Price 3,428
Intrinsic Value₹1,737.22
High / Low 6,410/3,151
Stock P/E22.8
Book Value 326
Dividend Yield2.19 %
ROCE57.5 %
ROE43.0 %
Face Value 10.0
PEG Ratio-1.29

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Sanofi India Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Sanofi India Ltd 7,894 Cr. 3,428 6,410/3,15122.8 3262.19 %57.5 %43.0 % 10.0
Shilpa Medicare Ltd 8,095 Cr. 414 502/26045.8 1250.12 %7.82 %4.21 % 1.00
Procter & Gamble Health Ltd 8,530 Cr. 5,139 6,739/4,70029.1 3732.43 %47.8 %36.4 % 10.0
Marksans Pharma Ltd 8,620 Cr. 190 271/15523.9 59.30.42 %20.0 %16.8 % 1.00
Sequent Scientific Ltd 8,768 Cr. 201 260/111203 32.20.00 %8.47 %3.21 % 2.00
Industry Average19,737.15 Cr1,103.0859.48201.130.36%16.35%15.16%6.10

All Competitor Stocks of Sanofi India Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 672736515491469511464524515536406475420
Expenses 505507393377370374348404397364311341330
Operating Profit 1672301221141001371161201181729513490
OPM % 25%31%24%23%21%27%25%23%23%32%23%28%22%
Other Income 3444578277412121439-223
Interest 0010000000001
Depreciation 101099999910109910
Profit before tax 1902641691861671691271131221659410283
Tax % 31%28%27%18%18%19%19%27%25%28%26%26%26%
Net Profit 1311901231521381371038291120707662
EPS in Rs 56.9182.7853.4366.1759.8759.3944.9635.7439.7051.9630.2233.0426.83

Last Updated: March 3, 2026, 2:56 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 25, 2026, 5:16 pm

MetricDec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024TTM
Sales 1,8091,9772,1932,3672,4602,7713,0712,9022,9572,7702,8512,0131,932
Expenses 1,4111,6391,8171,8321,9212,1462,4032,1862,1942,0662,0471,5221,413
Operating Profit 398339376535538625667716762704804491519
OPM % 22%17%17%23%22%23%22%25%26%25%28%24%27%
Other Income 83131218667988334556420483794
Interest 0002110222222
Depreciation 9297113119102103100826742403737
Profit before tax 3883734814805156106006771,258864846531484
Tax % 32%29%33%37%37%38%31%29%25%28%29%22%
Net Profit 265264322304326381414478944621603414356
EPS in Rs 115.30114.61139.78132.26141.74165.48180.09207.65410.61269.83262.26179.78154.92
Dividend Payout % 39%39%46%51%50%51%194%176%119%211%64%65%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year
YoY Net Profit Growth (%)
Change in YoY Net Profit Growth (%)

No data available for trend analysis.

Growth

Compounded Sales Growth
10 Years:0%
5 Years:-8%
3 Years:-12%
TTM:2%
Compounded Profit Growth
10 Years:8%
5 Years:0%
3 Years:-9%
TTM:1%
Stock Price CAGR
10 Years:8%
5 Years:0%
3 Years:11%
1 Year:-31%
Return on Equity
10 Years:24%
5 Years:32%
3 Years:41%
Last Year:47%

Last Updated: September 5, 2025, 1:25 pm

Balance Sheet

Last Updated: August 11, 2025, 2:43 pm

MonthDec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Jun 2025
Equity Capital 23232323232323232323232323
Reserves 1,3241,4631,6041,8602,0032,1962,4192,0962,2031,253992838759
Borrowings 0000000232524191921
Other Liabilities 532742778658751765802777811772681732436
Total Liabilities 1,8782,2282,4052,5412,7782,9843,2442,9183,0612,0721,7151,6121,239
Fixed Assets 699648877817769733499464334306315312309
CWIP 1362102234302117101324161816
Investments 0000000000200
Other Assets 1,0431,3691,5051,6901,9782,2302,7282,4442,7141,7431,3821,281914
Total Assets 1,8782,2282,4052,5412,7782,9843,2442,9183,0612,0721,7151,6121,239

Reserves and Borrowings Chart

Cash Flow

MonthDec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Cash from Operating Activity + 265213322435374412611559399231462438
Cash from Investing Activity + 6136-155-79-736627663165136-178-11
Cash from Financing Activity + -122-147-180-188-197-183-810-849-1,583-878-392-448
Net Cash Flow 205102-1316810429578341-533-612-109-21
Free Cash Flow 247184253379317337810574412221426413
CFO/OP 114%93%101%118%99%96%112%111%94%59%114%111%

Free Cash Flow

MonthDec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Free Cash Flow398.00339.00376.00535.00538.00625.00667.00693.00737.00680.00785.00472.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthDec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Debtor Days 242124222921271918172442
Inventory Days 151179173169151154127107110125254186
Days Payable 83122817911911010093105109112151
Cash Conversion Cycle 927811511261655433223316777
Working Capital Days 4326979171835-8-20-193520
ROCE %29%22%26%27%26%29%28%32%35%41%44%49%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%
FIIs 6.71%6.72%6.80%6.31%6.11%5.81%5.78%5.64%5.58%5.61%5.57%5.55%
DIIs 19.46%19.65%21.68%22.51%22.88%22.60%22.62%22.94%23.02%23.06%22.28%21.30%
Public 13.43%13.22%11.10%10.78%10.61%11.21%11.20%11.04%11.01%10.94%11.75%12.75%
No. of Shareholders 76,69471,51368,59862,87061,84967,66266,21166,40168,19666,79071,39575,813

Shareholding Pattern Chart

No. of Shareholders

Sanofi India Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
SBI Contra Fund 251,576 0.21 101.08161,0002025-12-07 15:45:1656.26%
Nippon India Pharma Fund 230,272 1.17 92.52236,0082025-12-08 04:19:42-2.43%
Nippon India Growth Mid Cap Fund 226,766 0.22 91.11N/AN/AN/A
Nippon India Small Cap Fund 213,992 0.13 85.98196,3422025-12-08 07:42:138.99%
Nippon India Multi Cap Fund 152,371 0.13 61.22152,3712025-04-22 17:25:210%
SBI ELSS Tax Saver Fund 147,988 0.19 59.46N/AN/AN/A
SBI Midcap Fund 128,577 0.23 51.66195,0822026-01-26 05:01:22-34.09%
Nippon India Innovation Fund 49,110 0.73 19.73N/AN/AN/A
Sundaram Dividend Yield Fund 11,397 0.51 4.58N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthDec 24Dec 23
FaceValue 10.0010.00
Basic EPS (Rs.) 179.46261.78
Diluted EPS (Rs.) 179.46261.78
Cash EPS (Rs.) 195.65279.35
Book Value[Excl.RevalReserv]/Share (Rs.) 374.17441.39
Book Value[Incl.RevalReserv]/Share (Rs.) 374.17441.39
Revenue From Operations / Share (Rs.) 875.301239.61
PBDIT / Share (Rs.) 220.57377.83
PBIT / Share (Rs.) 204.61360.61
PBT / Share (Rs.) 187.57367.61
Net Profit / Share (Rs.) 179.69262.13
NP After MI And SOA / Share (Rs.) 179.69262.13
PBDIT Margin (%) 25.1930.47
PBIT Margin (%) 23.3729.09
PBT Margin (%) 21.4229.65
Net Profit Margin (%) 20.5221.14
NP After MI And SOA Margin (%) 20.5221.14
Return on Networth / Equity (%) 48.0259.38
Return on Capital Employeed (%) 52.7277.98
Return On Assets (%) 25.6435.15
Asset Turnover Ratio (%) 1.210.00
Current Ratio (X) 1.571.92
Quick Ratio (X) 0.870.89
Inventory Turnover Ratio (X) 0.600.00
Dividend Payout Ratio (NP) (%) 0.00139.85
Dividend Payout Ratio (CP) (%) 0.00131.23
Earning Retention Ratio (%) 0.00-39.85
Cash Earning Retention Ratio (%) 0.00-31.23
Interest Coverage Ratio (X) 338.20511.18
Interest Coverage Ratio (Post Tax) (X) 235.27345.18
Enterprise Value (Cr.) 13783.3918147.83
EV / Net Operating Revenue (X) 6.856.37
EV / EBITDA (X) 27.1720.88
MarketCap / Net Operating Revenue (X) 6.996.51
Retention Ratios (%) 0.00-39.85
Price / BV (X) 16.3618.28
Price / Net Operating Revenue (X) 6.996.51
EarningsYield 0.020.03

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Sanofi India Ltd. is a Public Limited Listed company incorporated on 02/05/1956 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24239MH1956PLC009794 and registration number is 009794. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 1837.40 Cr. and Equity Capital is Rs. 23.00 Cr. for the Year ended 31/12/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsSanofi House, Mumbai Maharashtra 400072Contact not found
Management
NamePosition Held
Mr. Aditya NarayanChairman & Ind.Director
Mr. Deepak AroraManaging Director
Mr. Rodolfo HroszNon Executive Director
Mr. Vaibhav KarandikarNon Executive Director
Mr. Eric MansionNon Executive Director
Mr. Rachid AyariWholeTime Director & CFO
Mr. Mahadev GawadeWhole Time Director
Mrs. Usha ThoratIndependent Director
Mr. Rahul BhatnagarIndependent Director

FAQ

What is the intrinsic value of Sanofi India Ltd and is it undervalued?

As of 29 April 2026, Sanofi India Ltd's intrinsic value is ₹1737.22, which is 49.32% lower than the current market price of ₹3,428.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (43.0 %), book value (₹326), dividend yield (2.19 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Sanofi India Ltd?

Sanofi India Ltd is trading at ₹3,428.00 as of 29 April 2026, with a FY2026-2027 high of ₹6,410 and low of ₹3,151. The stock is currently near its 52-week low. Market cap stands at ₹7,894 Cr..

How does Sanofi India Ltd's P/E ratio compare to its industry?

Sanofi India Ltd has a P/E ratio of 22.8, which is below the industry average of 59.48. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Sanofi India Ltd financially healthy?

Key indicators for Sanofi India Ltd: ROCE of 57.5 % indicates efficient capital utilization; ROE of 43.0 % shows strong shareholder returns. Dividend yield is 2.19 %.

Is Sanofi India Ltd profitable and how is the profit trend?

Sanofi India Ltd reported a net profit of ₹414 Cr in Dec 2024 on revenue of ₹2,013 Cr. Compared to ₹944 Cr in Dec 2021, the net profit shows a declining trend.

Does Sanofi India Ltd pay dividends?

Sanofi India Ltd has a dividend yield of 2.19 % at the current price of ₹3,428.00. This is a relatively attractive yield for income-seeking investors.

Last Updated: April 25, 2026, 11:44 pm
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 500674 | NSE: SANOFI
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Sanofi India Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports